Last $4.90 USD
Change Today -0.10 / -2.00%
Volume 18.1K
VNRX On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

volitionrx ltd (VNRX) Snapshot

Open
$5.00
Previous Close
$5.00
Day High
$5.00
Day Low
$4.60
52 Week High
09/22/14 - $9.28
52 Week Low
06/9/14 - $1.30
Market Cap
70.8M
Average Volume 10 Days
10.9K
EPS TTM
--
Shares Outstanding
14.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VOLITIONRX LTD (VNRX)

Related News

No related news articles were found.

volitionrx ltd (VNRX) Related Businessweek News

No Related Businessweek News Found

volitionrx ltd (VNRX) Details

VolitionRX Limited, a development stage life sciences company, focuses on developing cancer detection blood tests for detecting and diagnosing cancer and other diseases. It develops two blood tests in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides; and three blood tests in the NuQ-V family to detect cancer and nucleosomes containing specific histone variants. The company also develops nine blood tests in the NuQ-M family to detect cancer by detecting nucleosomes containing modified histones, the proteins that package, and order DNA into nucleosomes; and five blood tests in the NuQ-A family to detect cancer by detecting nucleosome-protein adducts, as well as offers research kits. It develops HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help appropriate therapy; NuQ Endo endometriosis test; and NuQ clinical diagnostic products. VolitionRX Limited is based in Singapore.

7 Employees
Last Reported Date: 01/23/15

volitionrx ltd (VNRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: --
Chief Financial Officer and Treasurer
Total Annual Compensation: --
Chief Medical Officer and Head of US Operatio...
Total Annual Compensation: --
Secretary
Total Annual Compensation: --
Chief Scientific Officer of Belgian Volition ...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

volitionrx ltd (VNRX) Key Developments

VolitionRX Ltd Begins First Ovarian Cancer Detection Study

VolitionRx Limited announced it has signed an agreement to commence a pilot ovarian cancer study in collaboration with Singapore General Hospital. Blood and tissue samples collected from 40 patients will be assessed to establish the feasibility of VolitionRx's proprietary NuQ assays in detecting ovarian cancer. If this test proves to be accurate, it could offer hope as an early-stage screening tool. The collaboration with SGH will be VolitionRx's first to focus solely on patients from an Asian ethnic background. The Hospital will provide 20 matched blood and tissue samples from patients with ovarian cancer as well as blood samples from 20 healthy donors. The anonymised and blinded samples will be analysed by VolitionRx's team and will be the first matched tissue and blood samples to be assessed using its NuQ assays. On completion of the analyses, the data will be unblinded and together the parties will evaluate the performance of the test. VolitionRx will retain the intellectual property from the study. Other clinical trials assessing the effectiveness of Volition's assays include: A 4,800 patient retrospective symptomatic population study in colorectal cancer at Hvidovre Hospital, University of Copenhagen, Denmark. A 14,000 patient prospective screening study in colorectal cancer at Hvidovre Hospital, University of Copenhagen, Denmark. A 4,000 patient prospective study that involves patients with the 20 most prevalent cancers at University Hospital in Bonn, Germany. A 600 patient prospective confirmatory study in lung cancer at University Hospital in Bonn, Germany. A 250 patient prospective study in colorectal cancer at CHU-UCL Mont Godinne Hospital, Belgium. A retrospective study with MD Anderson, Texas, to establish the efficacy of VolitionRx's NuQ tests to distinguish anaplastic prostate cancer, a particularly aggressive form of the disease, from typical castration resistant prostate cancer, the less aggressive form. A prospective study with the University of Oxford, United Kingdom, to assess VolitionRx's NuQ tests for the diagnosis of endometriosis.

VolitionRX Ltd Completes Blinded Clinical Study

VolitionRx Limited announced that it has completed a blinded clinical study demonstrating that its NuQ® blood-based diagnostic platform is able to accurately detect 84% of early, surgically-treatable pancreatic cancers at high 92% specificity. The blinded study was conducted in collaboration with Lund University, Sweden and led by Roland Andersson, MD, PhD, Professor of Surgery and Vice-Dean, Faculty of Medicine. In the 60-patient study, blood samples were taken from 25 subjects with stage IIa or stage IIb pancreatic cancer as well as 25 healthy subjects and 10 subjects with other pancreatic diseases including chronic pancreatitis, intraductal papillary mucinous neoplasm (IPMN; a pre-cancerous condition which may lead to pancreatic cancer), serous cystadenoma (a benign tumor) and tubular adenoma in papilla vateri (another type of benign tumor). Analysis of the blood samples demonstrated that a panel of five NuQ® assays distinguished 21 of the 25 pancreatic cancer cases from healthy subjects (84% sensitivity), with only two false positive results among the 25 healthy subjects (92% specificity). Furthermore, the same panel of NuQ® assays was able to distinguish 19 of the pancreatic cancer cases (76% sensitivity) from all other subjects including healthy subjects and those with other pancreatic diseases with only a single false positive for one healthy subject and two false positives for subjects with other pancreatic diseases, one of which was a subject with pre-cancerous IPMN condition(91% specificity). These early data for NuQ® assays in pancreatic cancer show excellent clinical accuracy which may be improved further if used in conjunction with established CA19-9 ELISA tests. Nucleosomics® has been found to be effective for the detection of colorectal cancer as well as pre-cancerous colorectal polyps, prostate cancer, lung cancer and now, pancreatic cancer. The NuQ® tests utilize the company's proprietary Nucleosomics® platform, which identifies and measures circulating nucleosome structures for the presence of epigenetic cancer and signals within the blood. In addition to the pancreatic cancer study, other clinical trials assessing the effectiveness of VolitionRx's assays include: A 4,800 patient retrospective symptomatic population study in colorectal cancer at Hvidovre Hospital, University of Copenhagen, Denmark. A 14,000 patient prospective screening study in colorectal cancer at Hvidovre Hospital, University of Copenhagen, Denmark. A 4,000 patient prospective study that involves patients with the 20 most prevalent cancers at University Hospital in Bonn, Germany. A 600 patient prospective confirmatory study in lung cancer at University Hospital in Bonn, Germany; A 250 patient prospective study in colorectal cancer at CHU-UCL Mont Godinne Hospital, Belgium; A retrospective study with MD Anderson, Texas, to establish the efficacy of VolitionRx's NuQ® tests to distinguish anaplastic prostate cancer, a particularly aggressive form of the disease, from typical castration resistant prostate cancer (CRPC), the less aggressive form; A prospective study with the University of Oxford, United Kingdom, to assess VolitionRx's NuQ® tests for the diagnosis of endometriosis.

VolitionRX Ltd to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014

VolitionRx Limited announced that data from its pilot lung cancer study will be presented at the Science for Business BioWin Day 2014, being held November 26, 2014 in Louvain-la-Neuve, Belgium. The data come from VolitionRx's lung cancer pilot study, the samples for which were collected at the Pneumology department of the Centre Hospitalier Universitaire (CHU) de Liege in Belgium. The study assessed the ability of VolitionRx's proprietary NuQ(R) platform to detect lung cancer in both blood and sputum (airway secretions, or mucus coughed up from the lower respiratory tract). Currently, most lung cancers are first diagnosed based on symptoms, which generally reflect damage to the lungs' ability to function normally. Unlike mammography for breast cancer or colonoscopy for colorectal cancer, a screening tool for early-stage lung cancer is not available beyond the American Society of Clinical Oncology's (ASCO) guidelines suggesting annual screening with a low-dose computed tomography scan (LDCT) for individuals at high risk for lung cancer[i]. A simple, accurate, cost-effective test could help detect lung tumors in their earliest stages, when many physicians believe the tumors are most curable. VolitionRx's prospective study tested both blood and sputum samples from 46 individuals with either non-small cell lung cancer, chronic obstructive pulmonary disease (COPD) or with no disease (healthy) across various NuQ(R) assay panels. In sputum samples, the analysis demonstrated that VolitionRx's NuQ(R) test was able to detect 18 of 21 lung cancer cases (85%) with no false positive results for healthy subjects (0 of 13). Furthermore, NuQ(R) assays were able to discriminate lung cancer from COPD, another important respiratory disease linked to habitual smoking. The sputum assay data is age and smoking independent. In blood samples from the same patients adjusted for age and smoking risk, the NuQ(R) assays were able to detect 16 of the 21 patients with cancer (76%) with a single false positive result for a healthy subject (1 of 13). This test was also able to discriminate lung cancer from COPD. Overall, the technology in both blood and sputum samples appeared to detect both early and late stage lung cancer with high sensitivity and specificity, but further research with a larger number of samples is required to confirm this outcome. The NuQ(R) tests utilize the Company's proprietary Nucleosomics(R) platform, which identifies and measures circulating nucleosome structures for the presence of epigenetic cancer and signals within the blood, and now within sputum. In addition to this study, other clinical trials assessing the effectiveness of VolitionRx's assays include: A 4,800 patient retrospective symptomatic population study in colorectal cancer at Hvidovre Hospital, University of Copenhagen, Denmark. A 14,000 patient prospective screening study in colorectal cancer at Hvidovre Hospital, University of Copenhagen, Denmark. A 4,000 patient prospective study that involves patients with the 20 most prevalent cancers at University Hospital in Bonn, Germany. A 250 patient prospective study in colorectal cancer at CHU-UCL Mont Godinne Hospital, Belgium. A retrospective study with MD Anderson, Texas, to establish the efficacy of VolitionRx's NuQ(R) tests to distinguish anaplastic prostate cancer, a particularly aggressive form of the disease, from typical castration resistant prostate cancer (CRPC), the less aggressive form. A prospective study with the University of Oxford, United Kingdom, to assess VolitionRx's NuQ(R) tests for the diagnosis of endometriosis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNRX:US $4.90 USD -0.10

VNRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VNRX.
View Industry Companies
 

Industry Analysis

VNRX

Industry Average

Valuation VNRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4,572.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 4,721.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VOLITIONRX LTD, please visit www.volitionrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.